WGS — Stock Film
STOCK FILMSCENE 1/11WGS · $82.55
Stock Expert AI presents
WGS
GeneDx Holdings Corp
~4 min film100% real numbers0 jargon
WHAT DOES THIS COMPANY DO?
GeneDx Holdings Corp. A quick introduction.

On the stock market since 2020, it operates in the world of health and science. It has 1,300 employees. Now — the numbers.

on the stock market since 2020
1,300 employees
$1.8B market value
Revenue last year:
$0
The loss that same year:
$0
Sales don’t cover the costs; the gap drains from the cash pile every year.

The company is still in the product-building phase: its spending runs above its sales. That only changes once the product starts selling at scale.

THE SALES TREND
Sales are growing overall, with a pause along the way.

Average growth of 19% a year over the last 4 years. Red columns mark years that ended in a loss.

$212.2M
2021
$234.7M
2022
$202.6M
2023
$305.5M
2024
$427.5M
2025
In the vault right now:
$0
DEBT: $151.9M
At this pace, that money lasts about 8.1 years.

Before the clock runs out, either sales must climb sharply or new money must come in. For now, time is on the company’s side.

INSIDE THE REPORT CARD

We compared this company with its own sector across five subjects.

A score of 50 means class average.

BUSINESS QUALITY
63
average

Profit indicators sit around the sector average.

FINANCIAL STRENGTH
23
very weak

Clearly below the class average.

VALUATION
52
average

The price isn’t cheap next to earnings — that’s why this grade sits in the middle.

GROWTH
79
strong

Clearly above the class average — a step short of the very top.

PRICE MOMENTUM
60
average

The price is looking for direction — no strong breakout, no collapse.

WORTH WATCHING

Financial Strength: The cash-and-debt balance is thin; the buffer for hard times is slim.

THE COUNCIL REVIEW
9

angles, checked one by one.

The 2 that stand out are on screen; the rest came back neutral.

The council scores out of 10; report-card grades are out of 100.

WEAK SPOTS
The stock has lost its spark0/10
Executives aren’t buying3/10
WORTH WATCHING

Executive Buying: The trades send no strong signal of confidence.

THE FIVE-YEAR JOURNEY
A long and steep decline.

An investor who bought at the very peak is down 75% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.

1
THE BRIGHT SIDE · 1/3
Sales keep climbing

Over the last 3 years, sales grew about 22% a year on average.

2
THE BRIGHT SIDE · 2/3
The product is selling

Sales run at $427.5M a year. A small number, but proof the product has real buyers.

3
THE BRIGHT SIDE · 3/3
Delivers on expectations

It met or beat analyst expectations in 7 of the last 8 quarters — consistency is a promise kept.

1
THE RISKS · 1/3
Small scale, thin loss

A loss of $21.0M against $427.5M in annual sales.

2
THE RISKS · 2/3
A thin financial cushion

The balance sheet offers little cushion against a rough stretch. Report-card grade: 23/100.

3
THE RISKS · 3/3
The stock has lost its spark

Since the drop from its peak, buyer appetite hasn’t come back. Council score: 0/10.

FINALE · THE GRADE
F
0 / 100 · MoonshotScore

On our five-subject report card, WGS sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”

The takeaway: WGS is a high-risk stock — not yet profitable, and its future rides on its product catching on.

The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.

What would you like to do next?
Open the stock page →
This was a film — not investment advice.
Data: FMP & company filings
Aug 21, 2026 · stockexpertai.com · Stock Film